RxDoctor Payments Data

Anthony Salvo, MD

Family Medicine · Alcoa, TNNPI 1841236080

Payments from drug & device makers

$3,075in general payments, 2019–2025

Across 200 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$694
  • Lilly USA, LLC$442
  • Boehringer Ingelheim$235
  • Johnson & Johnson$230
  • Pfizer$197
  • Amgen$169
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,070100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,075 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,786
Medicare patients
300
Services billed
901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$93,642
JardianceEmpagliflozin54$68,822
EliquisApixaban67$67,364
MounjaroTirzepatide33$46,652
RybelsusSemaglutide16$38,011
TrulicityDulaglutide20$30,912
JanuviaSitagliptin Phosphate32$24,319
FarxigaDapagliflozin Propanediol13$21,051
TradjentaLinagliptin15$11,732
XareltoRivaroxaban16$11,631
Breo ElliptaFluticasone/Vilanterol14$6,699
Spiriva RespimatTiotropium Bromide11$6,587
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,531
SymbicortBudesonide/Formoterol Fumarate23$5,951
Tresiba Flextouch U-100Insulin Degludec12$5,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$694$131,65495 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$235$87,14180 claims
Lilly USA, LLCMounjaro, Trulicity$442$77,56453 claims
PfizerEliquis$197$67,36467 claims
AstraZenecaFarxiga, Symbicort$160$27,00236 claims
MerckJanuvia$101$24,31932 claims
Johnson & JohnsonXarelto$230$11,63116 claims
GSKBreo Ellipta$48$6,69914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →